Bladder Cancer

May 9th 2024

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

May 8th 2024

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

May 5th 2024

Patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with nadofaragene firadenovec experienced lasting responses to the therapy for up to 3 years.

May 1st 2024

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.